Nanosonics jumps 4% as it launches Trophon 3 and secures FDA approval for Coris, fueling upgrade demand and recurring revenue growth.
(AI video summary)
This video was created on 7 July 2025 for IG audiences by ausbiz.
Nanosonics has launched its Trophon 3 software for automated ultrasound disinfection, complemented by an update for current customers. Trophon 2 is approved in Europe, the United Kingdom (UK), Australia, and New Zealand, but awaits United States (US) Food and Drug Administration (FDA) approval.
RBC Capital Markets predicts increased sales and traceability revenues, setting a $5 target price. Shares rose 4% on this news, showing strong market enthusiasm.
Analysts view the new release as a positive. With 35,000 Trophon units globally, 10,000 of which are over seven years old, the Trophon 3 rollout is a significant revenue opportunity.
Nanosonics also gains from sales of hydrogen peroxide cartridges used in each disinfection cycle. The company’s recent FDA approval for the Coris device opens new growth avenues and eases prior market concerns.
Despite long-term potential, analysts caution that Nanosonics is a volatile investment. It is not cheap on a price-to-earnings (P/E) basis but shows promise in revenue and profitability. With an 'buy' recommendation and a $4.55 target price, analysts remain optimistic.
After a 35% share price increase this year, the leadership team, including former Cochlear executives, bolsters confidence. While welcoming the positive news, investors should stay mindful of volatility ahead.
This information has been prepared by IG, a trading name of IG Australia Pty Ltd. In addition to the disclaimer below, the material on this page does not contain a record of our trading prices, or an offer of, or solicitation for, a transaction in any financial instrument. IG accepts no responsibility for any use that may be made of these comments and for any consequences that result. No representation or warranty is given as to the accuracy or completeness of this information. Consequently any person acting on it does so entirely at their own risk. Any research provided does not have regard to the specific investment objectives, financial situation and needs of any specific person who may receive it. It has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication. Although we are not specifically constrained from dealing ahead of our recommendations we do not seek to take advantage of them before they are provided to our clients.